A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH ADVANCED LIVER CANCERS (MORPHEUS LIVER)

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506611-17-00

Acronym

GO42216

Enrollment

Registered

2024-05-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced liver cancers

Brief summary

1. ORR (determined by the investigator according to RECIST 1.1), 2. Incidence, nature, and severity of adverse events and laboratory abnormalities, 3. Change from baseline in vital signs and ECG parameters, 4. Change from baseline in targeted clinical laboratory test results

Detailed description

1. PFS, 2. OS after randomization, 3. OS at specific timepoints, 4. DOR, 5. Disease control

Interventions

DRUGRoActemra 20 mg/mL concentrate for solution for infusion

DRUGRO7791094

DRUGTecentriq 1 200 mg concentrate for solution for infusion

DRUGTPST-1120

DRUGRO7247669

DRUGRO7790118

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

DRUGADG126

DRUGTiragolumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
1. ORR (determined by the investigator according to RECIST 1.1), 2. Incidence, nature, and severity of adverse events and laboratory abnormalities, 3. Change from baseline in vital signs and ECG parameters, 4. Change from baseline in targeted clinical laboratory test results	—

Secondary

Measure	Time frame
1. PFS, 2. OS after randomization, 3. OS at specific timepoints, 4. DOR, 5. Disease control	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026